PTC Therapeutics, Inc. to acquire Sangamo Therapeutics, Inc.

PTC Therapeutics, Inc. has agreed to acquire the assets of Sangamo Therapeutics, Inc. in a strategic transaction valued at $111 million. The deal structure comprises a combination of cash consideration and potential earn-out payments, reflecting the parties' approach to valuing the target's intellectual property and development pipeline. Both entities are headquartered in the United States and operate within the healthcare sector, specifically focusing on therapeutic innovations. This asset sale represents a significant consolidation of resources for PTC Therapeutics, allowing it to integrate Sangamo’s proprietary technologies into its existing portfolio. The transaction was announced and completed on 17 September 2026, indicating an expedited regulatory or internal approval process that facilitated a swift closing without prolonged interim periods.

The immediate completion of the deal suggests that all necessary conditions precedent were satisfied concurrently with the announcement. By acquiring Sangamo’s assets rather than its equity, PTC Therapeutics has likely sought to isolate specific valuable components while avoiding potential liabilities associated with the target’s broader corporate structure. This approach is common in healthcare mergers where intellectual property rights are the primary drivers of value. The transaction is now fully executed and closed.